For the Inventor, By the Inventor

Enter inventor name

Woburn, MA, United States of America

Martin P Maguire

USPTO Granted Patents = 24

CIPO Patents = 1

EPO Patents = 1

Average Co-Inventor Count = 4.5

ph-index = 15

Forward Citations = 1,885(Granted Patents)

Location History:

King of Prussia, PA (US) (1997)
Louisville, KY (US) (2000)
Mont Clare, PA (US) (1996 - 2003)
Cambridge, MA (US) (2003 - 2004)
Woburn, MA (US) (2000 - 2009)

Company Filing History:

Aventis Pharmaceuticals Inc.

Rhone-poulenc Rorer Pharmaceuticals Inc.

Aventis Pharmaceuticals Products Inc.

Aventis Pharmaceuticals Product, Inc.

5. 1 out of 850

Millennium Pharmaceuticals Limited

6. 1 out of 330

Aventis Pharma Deutschland, Gmbh

7. 1 out of 4,179

Abbott Laboratories Corporation

Ore Pharmaceuticals Inc.

Years Active: 1996-2009

Loading Chart...

Loading Chart...

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7550597 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases (2009-06-23),

2. 7375125 - Melanocortin-4 receptor binding compounds and methods of use thereof (2008-05-20),

3. 6921821 - Antagonists of melanin concentrating hormone receptor (2005-07-26),

4. 6852712 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases (2005-02-08),

5. 6846815 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases (2005-01-25),

6. 6821962 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases (2004-11-23),

7. 6699873 - Melanocortin-4 receptor binding compounds and methods of use thereof (2004-03-02),

8. 6696434 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases (2004-02-24),

9. 6645969 - Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase (2003-11-11),

10. 6559313 - Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties (2003-05-06),

11. 6528526 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases (2003-03-04),

12. 6524347 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases (2003-02-25),

13. 6376472 - Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties (2002-04-23),

14. 6180632 - Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases (2001-01-30),

15. 6159978 - Quinoline and quinoxaline compounds which inhibit platelet-derived (2000-12-12),

Title: The Inventor Profile of Martin P Maguire

Introduction:

Martin P Maguire is a distinguished inventor based in Woburn, Massachusetts, known for his groundbreaking contributions to various fields.

Latest Patents:

Martin P Maguire holds several patents in the areas of technology and engineering, showcasing his innovative mindset and problem-solving abilities.

Career Highlights:

With a career spanning over two decades, Martin P Maguire has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing unique solutions.

Collaborations:

Throughout his career, Martin P Maguire has collaborated with leading research institutions, universities, and companies to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion:

In conclusion, Martin P Maguire's passion for innovation and his relentless drive to push the boundaries of what is possible make him a standout figure in the world of inventors. His contributions continue to inspire and shape the future of technology and beyond.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…